Respiratory Failure

A 68-year-old man with a history of COPD presents with a 3-day history of worsening dyspnea, productive cough, and increased sputum purulence. His family reports progressive drowsiness over the preceding several hours. On examination, he is tachypneic (RR 30/min), tachycardic (HR 118/min), and febrile (38.2°C), with SpO₂ 82% on room air. He is drowsy but arousable, follows commands, and can protect his airway. Accessory respiratory muscle use, bilateral wheezing, and reduced air entry are noted. Chest radiography shows hyperinflation without focal consolidation. Arterial blood gas analysis on room air reveals pH 7.25, PaCO₂ 72 mmHg, PaO₂ 48 mmHg, and HCO₃⁻ 31 mmol/L. Previous clinical records document persistent hypercapnia during stable periods, including a baseline ABG showing PaCO₂ 55 mmHg and HCO₃⁻ 30 mmol/L, consistent with chronic compensated hypercapnia. Diagnosis?

Diagnosis is Acute-on-Chronic Hypercapnic Respiratory Failure (Type 2 Respiratory Failure), precipitated by an Acute Exacerbation of COPD (AECOPD), with associated hypoxemia.

1. Definition

Respiratory failure occurs when the respiratory system cannot maintain adequate oxygenation, carbon dioxide elimination, or both.

It is classified into:

1.1 Type 1: Hypoxemic Respiratory Failure

1. PaO₂ <60 mmHg on room air (conventional threshold).
2. PaCO₂ usually normal or low.
3. Primary problem: Impaired oxygenation.

1.2 Type 2: Hypercapnic Respiratory Failure

1. PaCO₂ >45 mmHg indicates hypercapnia.
2. Primary problem: Inadequate alveolar ventilation.
3. Elevated PaCO₂ with acidemia suggests acute or acute-on-chronic respiratory acidosis.

In this patient: Elevated PaCO₂, acidemia, associated hypoxemia, and longitudinal documentation of chronic hypercapnia support acute-on-chronic hypercapnic respiratory failure.

2. Pathophysiology

Acute COPD exacerbation causes:

1. Increased airway resistance due to bronchospasm, inflammation, and mucus hypersecretion.
2. Air trapping and dynamic hyperinflation, increasing the work of breathing.
3. Respiratory muscle fatigue, reducing effective alveolar ventilation.
4. Ventilation-perfusion (V/Q) mismatch, causing hypoxemia.
5. CO₂ retention, resulting in respiratory acidosis.

Key physiological relationship:

PaCO₂ ∝ CO₂ production / Alveolar ventilation

Reduced alveolar ventilation increases PaCO₂.

Chronic hypercapnia leads to renal bicarbonate retention, while an acute rise in PaCO₂ produces worsening acidemia.

3. Clinical Features

3.1 Respiratory Features

1. Worsening dyspnea
2. Tachypnea
3. Accessory respiratory muscle use
4. Wheezing and reduced air entry
5. Hypoxemia
6. Increased cough, sputum production, or purulence

3.2 Features of Hypercapnia

1. Headache
2. Drowsiness
3. Confusion
4. Asterixis, sometimes present
5. Reduced consciousness in severe cases

3.3 Features of Impending Respiratory Arrest

1. Respiratory exhaustion
2. Weak or ineffective respiratory effort
3. Deteriorating consciousness
4. Bradypnea or apnea
5. Inability to protect the airway

In this patient: Drowsiness, tachypnea, accessory muscle use, and severe hypercapnia indicate significant ventilatory compromise.

4. Diagnostic Evaluation

4.1 Arterial Blood Gas Interpretation

Parameter	Result	Interpretation
pH	7.25	Acidemia
PaCO₂	72 mmHg	Hypercapnia
PaO₂	48 mmHg	Hypoxemia
HCO₃⁻	31 mmol/L	Elevated bicarbonate

Systematic interpretation:

1. Elevated PaCO₂ + low pH: Respiratory acidosis.
2. Elevated HCO₃⁻: Suggests renal compensation, although mixed metabolic disorders must be considered.
3. Repeated historical hypercapnia: Establishes a chronic hypercapnic component.
4. Acute PaCO₂ rise from 55 to 72 mmHg: Supports acute deterioration.
5. PaO₂ 48 mmHg: Confirms associated hypoxemia.

ABG conclusion: Acute-on-chronic hypercapnic respiratory failure with hypoxemia.

4.2 Initial Investigations

1. Chest X-ray: Evaluate pneumonia, pulmonary edema, and pneumothorax.
2. CBC and inflammatory markers: Assess infection and inflammation.
3. Electrolytes and renal function: Identify metabolic disturbances.
4. ECG: Evaluate arrhythmias or cardiac ischemia.
5. Sputum studies and viral testing: When clinically indicated.
6. Additional investigations: Guided by suspicion of pulmonary embolism, heart failure, or other precipitants.

In this patient: Fever and purulent sputum suggest an infectious COPD exacerbation. However, pneumonia and other cardiopulmonary precipitants must be considered.

A chest X-ray without focal consolidation does not completely exclude pneumonia.

Do not delay respiratory stabilization while awaiting investigations.

5. Management

Acute hypercapnic respiratory failure with respiratory acidosis is a medical emergency.

Management requires controlled oxygen, appropriate ventilatory support, treatment of the COPD exacerbation, and frequent reassessment.

5.1 Immediate Stabilization

1. Assess airway, breathing, and circulation.
2. Assess consciousness and airway protection.
3. Initiate continuous SpO₂, ECG, and hemodynamic monitoring.
4. Establish IV access.
5. Start controlled oxygen.
6. Assess the immediate need for NIV or invasive ventilation.

5.2 Controlled Oxygen Therapy

1. Target initial SpO₂ 88–92% in patients at risk of hypercapnic respiratory failure.
2. Use a Venturi mask or another appropriately titrated oxygen delivery device.
3. Adjust oxygen according to blood gases and clinical response.
4. Repeat blood gases approximately 30–60 minutes after initiating or significantly increasing oxygen, or sooner if clinical deterioration occurs.
5. Never withhold oxygen in severe hypoxemia.

Excessive oxygen may worsen hypercapnia through:

1. Worsening V/Q mismatch
2. Haldane effect
3. A smaller contribution from reduced hypoxic respiratory drive

5.3 Pharmacological Treatment

1. Short-Acting Bronchodilators

• Salbutamol (albuterol)
• Ipratropium
• Use a metered-dose inhaler with spacer when feasible.
• Alternatively, use air-driven nebulization when appropriate.
• Provide supplemental oxygen separately to maintain the prescribed SpO₂ target.
• Avoid unnecessary high-concentration oxygen from oxygen-driven nebulizers in patients at risk of CO₂ retention.

2. Systemic Corticosteroids

• Prednisone 40 mg orally daily for 5 days, when the oral route is feasible.
• An equivalent systemic corticosteroid regimen may be used when necessary.

3. Antibiotics

• Indicated in this patient because of increased sputum purulence and a severe COPD exacerbation meeting clinical criteria for NIV.
• Initiate antibiotics promptly when clinically indicated. Do not wait for NIV to be started.
• Select according to local resistance patterns, previous microbiology, and risk of resistant organisms.
• A treatment duration of approximately 5 days is commonly appropriate, individualized to clinical response.

4. Treat the Precipitating Cause

• Evaluate and treat infection or other identified triggers.
• Assess for pneumonia, heart failure, pulmonary embolism, or pneumothorax when clinically suspected.

5.4 Noninvasive Ventilation (NIV/BiPAP)

Bilevel NIV is recommended for appropriately selected patients with COPD exacerbation causing acute hypercapnic respiratory acidosis.

Consider NIV when:

1. pH ≤7.35
2. PaCO₂ >45 mmHg
3. Persistent respiratory distress, often RR >20–24/min despite appropriate medical treatment

In this patient: pH 7.25, PaCO₂ 72 mmHg, RR 30/min, and increased work of breathing provide a strong indication for prompt NIV, provided airway protection remains adequate.

Because the patient is drowsy, initiate NIV in an appropriately monitored acute-care setting with experienced staff and immediate access to invasive airway management.

Consider ICU or high-dependency care according to severity, clinical trajectory, and local resources.

NIV physiology:

Pressure support = IPAP − EPAP

Inspiratory pressure support assists alveolar ventilation and CO₂ clearance.

5.5 Contraindications or Major Concerns for NIV

1. Inability to protect the airway
2. Respiratory arrest
3. Uncontrolled vomiting
4. Inability to clear secretions
5. Severe hemodynamic instability
6. Rapid clinical deterioration

Hypercapnia-associated drowsiness is not necessarily an absolute contraindication to a closely monitored NIV trial.

NIV may be appropriate when the patient:

1. Can protect the airway.
2. Can manage secretions.
3. Tolerates the interface.
4. Can be monitored closely with immediate intubation capability.

NIV must not delay necessary intubation.

5.6 Monitoring NIV Response

Assess the clinical response continuously.

1. Monitor respiratory rate, work of breathing, oxygenation, mental status, and hemodynamics.
2. Repeat ABG within approximately 1–2 hours of NIV initiation.
3. Reassess blood gases after significant oxygen adjustments, commonly within 30–60 minutes.
4. Reassess immediately if clinical deterioration occurs.

Signs of NIV Success

1. Reduced respiratory rate and work of breathing
2. Improving pH
3. Falling PaCO₂ toward baseline
4. Improving mental status
5. Improving oxygenation

Signs of NIV Failure

1. Worsening respiratory acidosis
2. Persistent severe hypoxemia
3. Progressive respiratory exhaustion
4. Deteriorating consciousness
5. Inability to protect the airway

If the patient deteriorates, reassess immediately and proceed to invasive ventilation when indicated. Do not wait for the scheduled repeat ABG.

5.7 Inpatient Support and Exacerbation Prevention

1. Assess the need for pharmacological venous thromboembolism prophylaxis, unless contraindicated.
2. Monitor fluid balance, nutrition, and mobility according to clinical condition.
3. Review maintenance inhaled therapy before discharge.
4. Assess inhaler technique and adherence.
5. Address smoking cessation when applicable.
6. Review vaccination status, pulmonary rehabilitation eligibility, and follow-up arrangements.
7. Optimize strategies to prevent future exacerbations.

6. Major Complications

1. Progressive respiratory acidosis
2. Hypercapnic encephalopathy
3. Respiratory muscle exhaustion
4. Respiratory arrest
5. Cardiac arrhythmias
6. Hemodynamic deterioration
7. Need for invasive mechanical ventilation

7. Key Clinical Insight

COPD + worsening dyspnea + drowsiness + elevated PaCO₂ + acidemia strongly suggests acute hypercapnic respiratory failure.

Longitudinally documented chronic hypercapnia with an acute PaCO₂ rise and worsening acidemia supports an acute-on-chronic process.

In COPD exacerbation with hypercapnic respiratory acidosis, initiate controlled oxygen and prompt NIV when appropriate.

Treat a suspected bacterial exacerbation when antibiotics are clinically indicated. Do not delay treatment while arranging NIV.

Initial SpO₂ target: 88–92%.

SpO₂ DOES NOT MEASURE VENTILATION.

Normal oxygen saturation does not exclude dangerous hypercapnia.

Intubation is a clinical decision based on airway protection, gas exchange, respiratory effort, and clinical trajectory.

NEVER ALLOW AN UNSUCCESSFUL NIV TRIAL TO DELAY NECESSARY INTUBATION.

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2026 Report. Global Initiative for Chronic Obstructive Lung Disease; 2026.
2. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426. doi:10.1183/13993003.02426-2016.
3. O'Driscoll BR, Howard LS, Earis J, Mak V, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1–ii90. doi:10.1136/thoraxjnl-2016-209729.

CHRONIC KIDNEY DISEASE (CKD)

A 58-year-old man with a 15-year history of type 2 diabetes mellitus and hypertension presents with progressive fatigue, bilateral ankle swelling, nocturia, and reduced exercise tolerance. He has diabetic retinopathy and poorly controlled blood pressure. On examination, blood pressure is 158/92 mmHg, with bilateral pitting pedal edema and mild pallor. Investigations reveal serum creatinine 2.2 mg/dL, eGFR 33 mL/min/1.73 m², urine albumin-to-creatinine ratio (UACR) 520 mg/g, hemoglobin 10.2 g/dL, and serum potassium 4.6 mmol/L. Previous results demonstrate an eGFR of 36 mL/min/1.73 m² six months earlier. Urinalysis demonstrates proteinuria without hematuria or cellular casts. Renal ultrasonography demonstrates bilateral increased cortical echogenicity without hydronephrosis. Diagnosis?

Diagnosis is established Chronic Kidney Disease (CKD G3b) with current A3 albuminuria, most likely due to diabetic kidney disease, accompanied by hypertension, volume overload, and anemia requiring further evaluation.

The current UACR of 520 mg/g indicates A3 albuminuria; confirm the elevated UACR with a first-morning urine sample when feasible.

1. Definition

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function persisting for ≥3 months, with implications for health.

CKD is established by either of the following:

1. eGFR <60 mL/min/1.73 m² for ≥3 months
2. Persistent markers of kidney damage, including UACR ≥30 mg/g, urinary sediment abnormalities, or structural kidney abnormalities

CKD is classified using CGA:

• C: Cause
• G: GFR category
• A: Albuminuria category

GFR Categories (mL/min/1.73 m²)

1. G1: ≥90
2. G2: 60–89
3. G3a: 45–59
4. G3b: 30–44
5. G4: 15–29
6. G5: <15

Albuminuria Categories (UACR)

1. A1: <30 mg/g
2. A2: 30–<300 mg/g
3. A3: ≥300 mg/g

Important: G1–G2 alone do not establish CKD; persistent evidence of kidney damage is required.

In this patient, persistent eGFR reduction establishes CKD G3b, while the current UACR of 520 mg/g indicates A3 albuminuria. Confirm albuminuria with a first-morning urine specimen when feasible.

2. Pathogenesis

Progressive kidney injury involves:

1. Nephron injury and loss
2. Compensatory hyperfiltration in surviving nephrons
3. Glomerular hypertension and albuminuria
4. Inflammation and tubulointerstitial fibrosis
5. Progressive nephron loss and declining GFR

In diabetic kidney disease, chronic hyperglycemia contributes to:

1. Glomerular basement membrane thickening
2. Mesangial expansion
3. Glomerulosclerosis

Hypertension further accelerates kidney injury.

3. Clinical Features

3.1 Early CKD

1. Often asymptomatic
2. Hypertension
3. Nocturia
4. Albuminuria or proteinuria
5. Mild fatigue

3.2 Advanced CKD and Uremia

1. General: Anorexia, nausea, fatigue, metallic taste
2. Neurologic: Cognitive impairment, neuropathy, encephalopathy
3. Cardiovascular: Hypertension, volume overload, heart failure
4. Hematologic: Anemia and uremic platelet dysfunction
5. Metabolic: Hyperkalemia, metabolic acidosis, CKD-mineral and bone disorder
6. Skin: Pruritus; rarely, uremic frost

3.3 Important Complications

1. Anemia: Reduced erythropoietin production and other contributing factors
2. CKD-MBD: Phosphate retention, reduced calcitriol, and secondary hyperparathyroidism
3. Volume overload: Peripheral edema and pulmonary congestion
4. Hyperkalemia: Impaired potassium excretion
5. Metabolic acidosis: Reduced renal acid excretion

In this patient, fatigue, edema, reduced eGFR, marked albuminuria, and anemia are consistent with established CKD.

Important: Anemia should not automatically be attributed to CKD without excluding iron deficiency, bleeding, and other causes.

4. Diagnostic Evaluation

4.1 Laboratory Findings

1. Serum creatinine and eGFR: Assess kidney function; establish chronicity using previous measurements or other supporting evidence
2. UACR: Quantify albuminuria and predict progression
3. Albuminuria confirmation: Confirm elevated UACR with a first-morning urine sample when feasible, particularly if the initial specimen was collected randomly
4. Urinalysis and microscopy: Assess proteinuria, hematuria, and urinary casts
5. Electrolytes and bicarbonate: Identify hyperkalemia and metabolic acidosis
6. CBC, ferritin, and TSAT: Evaluate anemia and iron status
7. Calcium, phosphate, and PTH: Assess CKD-MBD when indicated
8. HbA1c: Evaluate glycemic control in diabetes

4.2 Imaging

1. Renal ultrasonography assesses kidney size, echogenicity, and obstruction
2. Small echogenic kidneys may support chronic parenchymal disease
3. Normal-sized kidneys do not exclude CKD, particularly in diabetic kidney disease

4.3 Establish Cause and Chronicity

1. Review previous creatinine, eGFR, and UACR measurements
2. Assess diabetes, hypertension, medication exposure, and family history
3. Evaluate alternative causes, including obstruction and glomerulonephritis, when indicated
4. Consider kidney biopsy if the presentation is atypical or the diagnosis remains uncertain

Important: AKI may coexist with CKD. A single abnormal eGFR does not establish chronicity.

In this patient, long-standing diabetes, diabetic retinopathy, persistent kidney dysfunction, substantial albuminuria, and bland urinary sediment strongly support diabetic kidney disease.

However, diabetic kidney disease remains the presumed etiology, rather than a histologically confirmed diagnosis.

5. Management

The major goals are to slow CKD progression, reduce cardiovascular risk, and manage complications.

5.1 Blood Pressure Control

1. Target standardized office SBP <120 mmHg, if tolerated
2. Individualize for frailty, orthostatic symptoms, and adverse effects
3. Reduce dietary sodium and optimize antihypertensive treatment

5.2 ACE Inhibitor or ARB

1. Recommended for diabetic CKD with A2–A3 albuminuria
2. Use an ACE inhibitor OR ARB at the maximally tolerated dose
3. Avoid combining ACEi and ARB
4. Check creatinine and potassium within 2–4 weeks after initiation or dose escalation
5. A creatinine increase >30% within four weeks warrants evaluation

This patient has a clear indication for ACEi/ARB therapy, provided no contraindication exists.

5.3 SGLT2 Inhibitors

1. Recommended for T2DM + CKD with eGFR ≥20 mL/min/1.73 m²
2. Also recommended for CKD with eGFR ≥20 and UACR ≥200 mg/g
3. Reduce kidney disease progression and cardiovascular events
4. A modest initial eGFR reduction may occur
5. Temporarily withhold during prolonged fasting, major surgery, or critical illness

This patient is eligible for SGLT2 inhibitor therapy, subject to contraindications and drug-specific prescribing criteria.

5.4 Additional Kidney-Protective Therapy

1. Finerenone: Consider in T2DM with persistent UACR >30 mg/g despite maximally tolerated ACEi/ARB, eGFR >25, and normal potassium
2. GLP-1 receptor agonist: Consider when indicated for glycemic control and cardiovascular benefit
3. Statin: Indicated in this patient with diabetes and CKD to reduce cardiovascular risk
4. Diet: Sodium <2 g/day for most adults; protein approximately 0.8 g/kg/day in nondialysis CKD G3–G5, with individualization
5. Avoid nephrotoxins: Particularly NSAIDs and unnecessary nephrotoxic medications

Medication safety:

• Finerenone: Monitor potassium at baseline, approximately four weeks after initiation or dose adjustment, and periodically thereafter
• Metformin: Reduce to a maximum of approximately 1,000 mg/day when eGFR is 30–44 mL/min/1.73 m²; discontinue when eGFR <30 mL/min/1.73 m²

5.5 Management of Complications

1. Volume overload: Sodium restriction and loop diuretics
2. Hyperkalemia: Correct contributing factors; initiate emergency treatment when severe
3. Metabolic acidosis: Consider oral bicarbonate for clinically important chronic acidosis, such as HCO₃⁻ <18 mmol/L; individualize treatment
4. Anemia: Check iron status, correct reversible causes, and consider ESA when indicated
5. CKD-MBD: Monitor calcium, phosphate, and PTH trends; correct modifiable abnormalities

Anemia treatment: In adults receiving ESAs, target Hb <11.5 g/dL during maintenance therapy. ESA initiation is individualized according to symptoms, dialysis status, and treatment risks.

5.6 Monitoring and Nephrology Referral

1. Monitor eGFR and UACR at least annually, more frequently in high-risk CKD
2. Evaluate significant or unexpected kidney function decline
3. Refer for eGFR <30, significant sustained progression, high-risk albuminuria patterns, or important CKD complications
4. Use the Kidney Failure Risk Equation (KFRE) in CKD G3–G5:
• 5-year risk approximately 3–5% or higher: Supports nephrology referral
• 2-year risk >10%: Supports multidisciplinary kidney care
• 2-year risk >40%: Supports kidney replacement therapy preparation

Important: CKD G3b with current A3 albuminuria indicates increased progression risk, but the KFRE must be calculated to quantify this patient's predicted kidney failure risk.

His UACR of 520 mg/g without hematuria does not independently meet the KDIGO ACR >700 mg/g or significant albuminuria-plus-hematuria referral criteria.

Nevertheless, nephrology consultation may be appropriate based on overall risk, progression, treatment complexity, or complications.

6. Major Complications

1. Cardiovascular disease: Myocardial infarction, stroke, and heart failure
2. Progressive kidney failure: Declining GFR and possible need for kidney replacement therapy
3. Hyperkalemia: Potentially life-threatening arrhythmias
4. Metabolic acidosis: Chronic acid-base disturbance
5. Anemia: Fatigue and reduced functional capacity
6. CKD-MBD: Secondary hyperparathyroidism, bone disease, and vascular calcification
7. Volume overload: Hypertension, edema, and pulmonary edema
8. Uremic complications: Encephalopathy, pericarditis, and platelet dysfunction

Urgent Dialysis Indications: AEIOU

• A: Severe refractory acidosis
• E: Dangerous or refractory electrolyte abnormalities
• I: Selected dialyzable intoxications, mainly acute poisoning
• O: Refractory fluid overload
• U: Uremic pericarditis, encephalopathy, or severe refractory symptoms

Dialysis initiation depends on clinical indications, symptoms, laboratory findings, and patient preferences—not eGFR alone.

7. Key Clinical Insight

Persistent eGFR <60 mL/min/1.73 m² for ≥3 months OR persistent markers of kidney damage establishes CKD.

Classify CKD using Cause + GFR + Albuminuria (CGA).

Higher albuminuria is associated with a greater risk of CKD progression and cardiovascular events.

In this patient:

Persistent eGFR reduction (currently 33 mL/min/1.73 m²) establishes CKD G3b; current UACR 520 mg/g indicates A3 albuminuria. Diabetic kidney disease is the most likely cause.

Confirm elevated UACR with a first-morning urine sample when feasible.

Control BP → Initiate ACEi/ARB and SGLT2i when indicated → Reduce cardiovascular risk → Manage complications → Monitor progression → Assess kidney failure risk.

Do not initiate dialysis based on eGFR alone.

References

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018.
2. de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–3090. doi:10.2337/dci22-0027.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Kidney International. 2026;109(1S):S1–S99. doi:10.1016/j.kint.2025.06.006.